Watchful Waiting or Watchful Progression? Prostate Specific Antigen Doubling Times and Clinical Behavior in Patients With Early Untreated Prostate Carcinoma

Duncan B. McLaren(NHS Lothian), Tom Pickles, Michael McKenzie(Provincial Health Services Authority), Gillian Duncan(University of British Columbia)

The Journal of Urology

October 1, 1998

10.1016/s0022-5347(01)62625-9

Cited by 94

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

|The Lancet|2015|2k

Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer

|International Journal of Radiation Oncology*Biology*Physics|2016|736

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

|The Lancet Oncology|2019|649

Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy

|International Journal of Radiation Oncology*Biology*Physics|2008|532

ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer

|International Journal of Radiation Oncology*Biology*Physics|2017|319